In vivo fate of lipid-silybin conjugate nanoparticles: Implications on enhanced oral bioavailability

LDCs-containing SLNs can be degraded to release LDCs, which are then taken up by enterocytes, further broken down to SB, and finally transported to systemic circulation. This enterocyte-to-portal vein route accounts for a major part of enhanced oral bioavailability, whereas the contribution of the M cell/lymphatics route is not as remarkable.206